



April 18, 2016

✓ **BSE Limited,**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

*Dear Sir,*

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a press release as regards launch of Fyavolv™ Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg) having received US FDA approval, to market a generic version of Warner Chilcott's Femhr® Tablets.

This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,  
**For LUPIN LIMITED**

*For*   
**R. V. SATAM**  
**COMPANY SECRETARY**

**Encl: a/a**

LUPIN LIMITED

Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098 India. Tel.: (91-22) 6640 2323  
Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

## **Lupin Launches Generic Femhrt® Tablets in the US**

**Mumbai, Baltimore, April 18, 2016:** Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Fyavolv™ Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg) having received an approval from the United States Food and Drug Administration (FDA) earlier to market a generic version of Warner Chilcott's Femhrt® Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg).

Lupin's Fyavolv™ Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg) are the AB rated generic equivalent of Warner Chilcott's Femhrt® Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg). It is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis.

Femhrt® had US sales of USD 39 million (IMS MAT December 2015).

### **About Lupin Limited**

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 6<sup>th</sup> largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions, IMS Health) and the 3<sup>rd</sup> largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 9<sup>th</sup>) and South Africa (ranked 4<sup>th</sup> – IMS Health).

For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion) and Rs. 24,032 million (USD 393 million) respectively. Please visit <http://www.lupin.com> for more information.

You could also follow us on Twitter – [www.twitter.com/lupinlimited](http://www.twitter.com/lupinlimited)

**CIN:** L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.

### **For further information or queries please contact -**

Shamsher Gorawara

Head – Corporate Communications

Ph: +91-98 20 338 555

Email: [shamshergorawara@lupin.com](mailto:shamshergorawara@lupin.com)

or

## Press Release



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Alpesh Dalal  
Head – M & A and Investor Relations  
Lupin Limited  
Ph: +91 98 20 023 511  
Email: [alpeshdalal@lupin.com](mailto:alpeshdalal@lupin.com)

*[\\*Safe Harbor Statement](#)*

*Femhrt® is the registered trademark of Warner Chilcott.*